Headquartered in Geneva, Switzerland, Selexis is a leading biotechnology company dedicated to the development of innovative technologies and expert services for mammalian cell line development. Selexis offers comprehensive and rapid solutions for stable, high yield mammalian cell lines used in recombinant protein manufacturing of therapeutic drugs. The Company's unique SURE Cell Line DevelopmentSM services and technology, which includes Selexis’ patented Selexis Genetic Elements™, reduces traditional cell line development (e.g. DHFR) from 12 months to ~5 weeks* with an increase in expression more than 20 fold without any change in the scale-up process.
The patented Selexis Genetic Elements™ improves the speed, yield and stability of production cell lines. Selexis Genetic Elements™ allows stable cell line development in ~5 weeks (after transfection to isolated cell clone). Additionally, Selexis Genetic Elements™ has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 20 fold.
* After transfection to isolating cell clones.
YEAR FOUNDED
2001
FINANCIALS
Selexis SA is a privately held company. Selexis SA has no securities registered under the United States Securities Act of 1933.
INDUSTRIES
Biomanufacturing
Biopharmaceuticals
Biotechnology
Cell Line Development for Protein Manufacturing
Cell Therapies
Contract Manufacturing
Clinical Research
Pharmaceutical
Vaccines
CORPORATE HEADQUARTERS
Selexis SA
18 chemin des Aulx
1228 Plan-les-Ouates
Switzerland
Telephone: +41 (0)22 308 93 60
Fax: +41 (0)22 308 93 61